Abstract
Background: Wilson disease is genetic disorder of copper metabolism which causes hepatic & neurologic manifestations mainly. Chelation therapy specially penicillamine is given as first line treatment in children with symptomatic wilson disease. Objective: To assess the safety & the clinical outcome of treatment with low dose penicillamine in Neurologic wilson disease
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
